Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass balance, pharmacokinetics, and metabolism study of intravenous [14C]-RO7223280 in healthy male volunteers
NL-OMON51844Completed
- Sponsor
- Roche
- Start
- Jul 2022
- Modality
- Cyclic Peptides → Modified Peptides → Peptides
- Countries
- 1
01
Overview
Open-label, single-arm trial of zosurabalpin in Acinetobacter baumannii infection, sponsored by Roche. Primary endpoints: Mass balance and elimination of RO7223280 and Pharmacokinetics of RO7223280 and drug-related radioactivity. Started Jul 2022; status: completed.
02
Drugs
zosurabalpin
03
Conditions
Acinetobacter baumannii infection
Beyond the preview
Go deeper on NL-OMON51844.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51844.